Hormonal composition for local application system action

 

The invention relates to medicine, more specifically to the hormonal composition for local application system action to correct the deficiency POCs women in the premenopausal period and hormonal therapy for women in menopause, characterized in that it contains as active principle a synthetic progestogen that is derived 19-norprogesterone, carrier engaged in systemic passage of the indicated active agent selected from the group comprising solubilizers agent, an absorption promoter, film-forming agent, gelling agent, or mixtures thereof, combined or mixed with suitable excipients for pharmaceutical forms, such as gel and/or film. 14 C.p. f-crystals, 14 tab., 12 Il.

Description text in facsimile form (see graphic part).

Claims

1. Hormonal composition in the form of a gel or film-forming gel with systemic action to correct the deficiency of progesterone in women premenopausal and gormonozavisimye women in menopause, characterized in that it contains 0.05-1% by weight of the total weight of the composition, m is e esters, at least one carrier, allowing the system to the passage of the active principle selected from the group comprising solubilizers agent, an absorption promoter, film-forming agent, a gelling agent and, optionally, a diluent.

2. Hormonal composition with a systemic effect on p. 1, characterized in that it contains acetate nomegestrol.

3. Hormonal composition with a systemic effect on p. 1, characterized in that it contains a number of nomegestrol or one of its simple or complex esters is 0.4% by weight of the total weight of the composition.

4. Hormonal composition with a systemic effect according to any one of paragraphs. 1-3, characterized in that solubilizers agent selected from the group comprising water, alcohols, propylene glycol,8/S10polyoxyethylenesorbitan or mixtures thereof.

5. Hormonal composition with a systemic effect according to any one of paragraphs. 1-4, characterized in that solubilizers agent is a three-component mixture of 95othe ethanol/water/propylene glycol in which the percentage 95oethanol ranges from 30 to 50%, water 30% to 60% and propylene glycol from 2 to 20%.

6. Hormonal composition with a systemic effect according to any one of paragraphs. 1-5, ood/Labrasol/propylene-glycol, in which the percentage 95oethanol ranges from 30 to 50%, water 30% to 60%, Labrasol from 3 to 7% and propylene glycol from 2 to 20%.

7. Hormonal composition with a systemic effect according to any one of paragraphs. 1-6, characterized in that the absorption promoter selected from the group comprising isopropylideneglycerol,-tocopherolacetate 1000 succinate and monotropy ether of diethylene glycol.

8. Hormonal composition with a systemic effect on p. 7, wherein the absorption promoter is isopropylideneglycerol.

9. Hormonal composition with a systemic effect according to any one of paragraphs. 1-8, characterized in that the gelling agent is selected from the group comprising cellulose derivatives and acrylic derivatives.

10. Hormonal composition with a systemic effect on p. 9, characterized in that the derivative of cellulose is hypromellose.

11. Hormonal composition with a systemic effect on p. 10, characterized in that the acrylic derivative is carbomer.

12. Hormonal composition with a systemic effect according to any one of paragraphs. 1-11, characterized in that the film-forming agent selected from the group including the second composition with a systemic effect on p. 12, characterized in that the derivative of cellulose is acetylsuccinate hydroxypropylmethylcellulose.

14. Hormonal composition with a systemic effect on p. 13, characterized in that the methacrylic derivative is a water dispersion of an anionic copolymer of methacrylic acid and ethyl acrylate.

15. Hormonal composition with a systemic effect according to any one of paragraphs. 1-14, characterized in that it is in the form of a gel or film-forming gel and it contains a water-alcohol mixture, 8% propylene glycol and 3% isopropylideneglycerol.

 

Same patents:
The invention relates to medicine and can be used in dentistry

The invention relates to medicine, namely to the adhesive polymer matrix applied to the device for percutaneous introduction of progestogenic, and this matrix is composed of a single layer (2) or the following sequential layers: if necessary, layer (1), called anchoring, formed of silicone polymer; a layer (2) formed of silicone polymer enriched Trimegestone and/or one or more pharmaceutically acceptable derivatives and, if necessary, a plasticizer; if necessary, the layer (3), called adhesive formed of silicone polymer

The invention relates to medicine, to compositions containing polar lipid composition on the basis of nicotine in liquid crystals and colloidal dispersions and their predecessors or secondary products, which are in contact with fluid body and/or under the influence of body temperature into liquid crystals, or a mixture of liquid crystals, which acts as a matrix with controlled release of nicotine, suitable for Smoking cessation and/or replacement area

The invention relates to medicine, and is intended for the treatment of inflammatory diseases of different etiology
The invention relates to medicine, namely to dentistry
The invention relates to dentistry, concerns the creation of a medical adhesive tapes for fixing laminar prostheses and method of their preparation

The invention relates to medicine, in particular to the pharmaceutical industry

The invention relates to the field of pharmaceutical industry and relates to a composition for the normalization of the internal microflora of the vagina and the gastrointestinal tract with antimicrobial and anti-inflammatory action

The invention relates to medicine, in particular to wound healing tool ointment thiotriazoline used in dentistry, surgery and dermatology

The invention relates to medicine, specifically to the means which have an antimicrobial effect on local purulent-inflammatory processes of the soft tissues and used in surgery, dermatology, obstetrics, gynecology, otolaryngology
The invention relates to medicine, namely to create medications for the treatment of burns
The invention relates to the field of pharmacy and relates to antifungal agents and method of its production

Cream vitus-factor" // 2207137
The invention relates to means for the prevention of diseases such as prostatitis, sexual weakness, prevention of diseases of the rectum (the inflammation, hemorrhoids), and to reduce the risk of diseases of the pelvic organs, especially gynecological

The invention relates to the field of medicine and is concerned with the obtaining drugs antifungal activity in the form of a cream based on terbinafine
The invention relates to the field of medicine and relates to a means and method for the treatment of patients with melanomas of the skin

The invention relates to medicine, in particular to pharmacological agents and treatment joints

Centuries-old medical experience shows that virtually every man occasionally pain in the back and joints of the limbs (Nordemar P
Up!